athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies. the company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. our business includes medical technology innovation centers and a unique manufacturing supply chain across both china and north america. through the connected innovation and manufacturing supply chain presence, we can identify, develop and deliver proprietary medical technology across continents and multiple regulatory environments.
Company profile
Ticker
ATNXQ
Exchange
Website
CEO
Johnson Lau
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Kinex Pharmaceuticals LLC, Kinex Pharmaceuticals, Inc.
SEC CIK
Corporate docs
Subsidiaries
Athenex API Limited • ATHENEX CIDAL HOLDINGS • ATHENEX CIDAL PANAMA, S.A. • Athenex Cidal Colombia S.A.S. • Athenex Cidal Costa Rica S.A. • Athenex Cidal Ecuador ATHENEXCUA S.A. • Athenex Cidal Guatemala S.A. • Athenex Euro Limited • Athenex HK Innovative Limited • Athenex Manufacturing China Limited ...
ATNXQ stock data
Latest filings (excl ownership)
8-K
Bankruptcy or Receivership
2 Oct 23
8-K
Departure of Directors or Certain Officers
17 Aug 23
8-K
Entry into a Material Definitive Agreement
18 Jul 23
25-NSE
Exchange delisting
10 Jul 23
NT 10-Q
Notice of late quarterly filing
23 May 23
8-K
Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process
22 May 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
3 May 23
10-K/A
2022 FY
Annual report (amended)
28 Apr 23
8-K
Departure of Directors or Certain Officers
25 Apr 23
8-K
Amendments to Articles of Incorporation or Bylaws
31 Mar 23
Transcripts
ATNXQ
Earnings call transcript
2022 Q2
29 Jul 22
ATNXQ
Earnings call transcript
2022 Q1
10 May 22
ATNXQ
Earnings call transcript
2021 Q4
17 Mar 22
ATNXQ
Earnings call transcript
2021 Q3
7 Nov 21
ATNXQ
Earnings call transcript
2021 Q2
7 Aug 21
ATNXQ
Earnings call transcript
2021 Q1
8 May 21
ATNXQ
Earnings call transcript
2020 Q4
1 Mar 21
ATNXQ
Earnings call transcript
2020 Q3
5 Nov 20
ATNXQ
Earnings call transcript
2020 Q2
9 Aug 20
ATNXQ
Earnings call transcript
2020 Q1
9 May 20
Latest ownership filings
Financial summary
Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 35.64 mm | 35.64 mm | 35.64 mm | 35.64 mm | 35.64 mm | 35.64 mm |
Cash burn (monthly) | 1.58 mm | 1.34 mm | 8.68 mm | 8.30 mm | 3.94 mm | 5.81 mm |
Cash used (since last report) | 24.99 mm | 21.13 mm | 137.01 mm | 130.94 mm | 62.11 mm | 91.77 mm |
Cash remaining | 10.65 mm | 14.51 mm | -101.37 mm | -95.31 mm | -26.48 mm | -56.13 mm |
Runway (months of cash) | 6.7 | 10.8 | -11.7 | -11.5 | -6.7 | -9.7 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 5 |
Opened positions | 0 |
Closed positions | 25 |
Increased positions | 0 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 40.98 mm |
Total shares | 10.33 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
IPZYF IP | 10.25 mm | $38.05 mm |
Acadian Asset Management | 48.56 k | $6.00 k |
National Asset Management | 22.50 k | $2.93 mm |
MCQEF Macquarie | 3.50 k | $0.00 |
IFP Advisors | 2.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 May 23 | Lau Johnson Yiu Nam | Common Stock | Grant | Acquire A | No | No | 1.36 | 8,382 | 11.40 k | 250,397 |
5 May 23 | Timothy DeVere Cook | Common Stock | Grant | Acquire A | No | No | 1.36 | 368 | 500.48 | 4,140 |
5 May 23 | Kwan Rudolf | Common Stock | Grant | Acquire A | No | No | 1.36 | 3,603 | 4.90 k | 49,816 |
21 Apr 23 | Timothy DeVere Cook | Common Stock | Grant | Acquire A | No | No | 1.305 | 383 | 499.82 | 3,772 |
21 Apr 23 | Stephanie A Davis | Common Stock | Grant | Acquire A | No | No | 1.305 | 3,642 | 4.75 k | 8,015 |